Brief: XBiotech Announces Agreement To Sell True Human Antibody Bermekimab Targeting Il-1A To Janssen
07/12/2019 08:09
Dec 7 (Reuters) - Xbiotech Inc XBIT.O :
* PRESS RELEASE - XBIOTECH ANNOUNCES AGREEMENT TO SELL TRUE
HUMAN
ANTIBODY BERMEKIMAB TARGETING IL-1A TO JANSSEN
* XBIOTECH MAY RECEIVE UP TO $600 MILLION IN POTENTIAL
MILESTONE
PAYMENTS
* XBIOTECH -CO EXPECTS TO GENERATE ADDITIONAL REVENUE FROM
MANUFACTURING SUPPLY AGREEMENT, CLINICAL SERVICES AGREEMENT WITH
JANSSEN OVER NEXT 2 YEARS
Source text for Eikon: ID:nGNX5smz45
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke